Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a worldwide common malignancy with poor prognosis. Several studies have aimed at identification of appropriate biomarkers for early detection of this cancer. Cancer-testis antigens (CTAs) as a novel group of tumor-associated antigens have been demonstrated to be exp...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2018-04, Vol.10 (5), p.411-421
Main Authors: Seifi-Alan, Mahnaz, Shamsi, Roshanak, Ghafouri-Fard, Soudeh
Format: Article
Language:English
Subjects:
Antigen (tumor-associated)
Antigens
biomarker
Biomarkers
Bladder
Cancer therapies
cancer-testis antigen
Cell adhesion & migration
Clinical trials
Cytoplasm
Esophagus
Genes
Hepatocellular carcinoma
Immune response
Immunotherapy
Kinases
Liver cancer
Localization
Malignancy
Medical prognosis
Melanoma
Peripheral blood
Physiology
Proteins
Sperm
Spermatogenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is a worldwide common malignancy with poor prognosis. Several studies have aimed at identification of appropriate biomarkers for early detection of this cancer. Cancer-testis antigens (CTAs) as a novel group of tumor-associated antigens have been demonstrated to be expressed in HCC samples as well as peripheral blood samples from these patients but not in the corresponding adjacent noncancerous samples. Such pattern of expression has provided them an opportunity to be used as immunotherapeutic targets. The detection of spontaneous immune responses against CTAs in HCC patients has prompted design of CTA-based immunotherapeutic protocols in these patients. The results of some clinical trials have been promising in a subset of patients.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2017-0154